文献速递产科妇科

产后6个月盆腔器官脱垂相关的产时危险因素

Intrapartum risk factors associated with pelvic organ prolapse at 6 months postpartum.
PubMed 文献 · Am J Obstet Gynecol MFM · 2022-07-16

该研究为多中心随机临床试验的预设二次分析,纳入≥37周孕龄、接受椎管内镇痛的初产妇,评估产时因素与产后6个月盆腔器官脱垂(POP-Q分期≥2期)的关联。结果显示,引产使用前列腺素与脱垂风险升高相关(aOR 2.15,95%CI 1.18-3.91,P<.01),剖宫产与脱垂风险降低相关(aOR 0.12,95%CI 0.02-0.90),第一产程和第二产程时长及用力时长与脱垂无显著关联。

要点

  • 引产使用前列腺素与产后6个月POP-Q分期≥2期脱垂风险升高相关(aOR 2.15,95%CI 1.18-3.91,P<.01)。
  • 剖宫产与产后6个月POP-Q分期≥2期脱垂风险降低相关(aOR 0.12,95%CI 0.02-0.90)。
  • 第一产程和第二产程时长及用力时长与产后6个月POP-Q分期≥2期脱垂无显著关联。

核心结论

  • 第一产程和第二产程的管理(包括时长)与产后6个月POP-Q分期≥2期脱垂无显著关联。
  • 引产使用前列腺素与脱垂风险升高相关,可能并非直接作用于脱垂风险,而是其他产时特征的替代指标,值得进一步探索。
  • 剖宫产与产后6个月POP-Q分期≥2期脱垂风险降低相关,与既往文献一致。

研究设计与样本

  • 研究为多中心随机临床试验(延迟用力与立即用力比较)的预设二次分析,在美国6家学术和社区医院开展。
  • 纳入≥37周孕龄、产程中接受椎管内镇痛的初产妇。
  • 在产后6周和6个月进行盆腔器官脱垂定量(POP-Q)评估。
  • 主要结局为产后6个月POP-Q分期≥2期脱垂。
  • 采用多变量logistic回归校正随机分组、巨大儿和母亲年龄。

主要发现

  • 941名女性参与盆底随访,其中793名在产后6周完成POP-Q评估,91/793名(11.5%)为POP-Q分期≥2期脱垂。
  • 728名女性在产后6个月随访,其中58/728名(8.0%)为POP-Q分期≥2期脱垂。
  • 引产使用前列腺素与产后6个月脱垂风险升高相关(校正OR 2.15,95%CI 1.18-3.91,P<.01)。
  • 剖宫产与产后6个月脱垂风险降低相关(校正OR 0.12,95%CI 0.02-0.90)。
  • 第一产程时长和类型(自然临产与引产)以及第二产程时长和用力时长与POP-Q分期≥2期脱垂无显著关联。

关键数值与推荐

  • 脱垂定义为产后6个月POP-Q评估分期≥2期。
  • 引产使用前列腺素的校正OR为2.15(95%CI 1.18-3.91,P<.01)。
  • 剖宫产的校正OR为0.12(95%CI 0.02-0.90)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pregnancy and childbirth are known risk factors associated with the development of pelvic organ prolapse; specific intrapartum risk factors are not well characterized. OBJECTIVE: This study aimed to determine intrapartum factors associated with increased risk of pelvic organ prolapse identified after delivery. STUDY DESIGN: A planned secondary analysis of a multicenter randomized clinical trial of delayed vs immediate pushing among nulliparous women at ≥37 weeks of gestation in labor with neuraxial analgesia was conducted at 6 academic and community hospitals in the United States. Intrapartum characteristics were identified, and Pelvic Organ Prolapse Quantification assessments at 6 weeks and 6 months after delivery were performed. The primary outcome was pelvic organ prolapse, defined as stage 2 or greater prolapse using the Pelvic Organ Prolapse Quantification assessment at 6 months. Multivariable logistic regression was used to refine risk estimates while adjusting for randomization group, macrosomia, and maternal age. RESULTS: Among the 941 women participating in the pelvic floor follow-up, 793 women had Pelvic Organ Prolapse Quantification assessments at 6 weeks with 91 of 793 women (11.5%) demonstrating stage 2 or greater prolapse. Of the 728 women followed up at 6 months, stage 2 or greater prolapse was identified in 58 of 728 women (8.0%). Prostaglandin use for induction of labor was associated with an increased risk at 6 months (adjusted odds ratio, 2.15; 95% confidence interval, 1.18-3.91; P<.01). The length and type (spontaneous vs induced) of the first stage of labor were not significantly associated with stage 2 or greater prolapse. Moreover, increased length of the second stage of labor and duration of pushing were not associated with stage 2 or greater prolapse. After adjusting for confounding factors, cesarean delivery was protective of pelvic organ prolapse at 6 months (adjusted odds ratio, 0.12; 95% confidence interval, 0.02-0.90). CONCLUSION: The management of the first and second stages of labor, including time length, was not associated with stage 2 or greater prolapse at 6 months. The findings that prostaglandin exposure was associated with increased risk likely were not directly affecting the risk of prolapse but may be surrogates for other labor features that deserve exploration. Cesarean delivery was associated with protection from stage 2 or greater pelvic organ prolapse at 6 months, consistent with previous literature.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Saucedo AM, Richter HE, Gregory WT, et al. Intrapartum risk factors associated with pelvic organ prolapse at 6 months postpartum. Am J Obstet Gynecol MFM. 2022. PMID: 35853583. doi:10.1016/j.ajogmf.2022.100692

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。